# Spatial Growth Rate of Emerging SARS-CoV-2 Lineages in England, September 2020–December 2021

M.R. Smallman-Raynor<sup>1,\*</sup>, A.D. Cliff<sup>2</sup> and The COVID-19 Genomics UK (COG-UK)

Consortium<sup>3,†</sup>

#### Affiliations

- <sup>1</sup> School of Geography, University of Nottingham, United Kingdom
- <sup>2</sup> Department of Geography, University of Cambridge, United Kingdom
- <sup>3</sup> https://www.cogconsortium.uk
- \*Corresponding author: <u>matthew.smallman-raynor@nottingham.ac.uk</u>
- † Full list of consortium names and affiliations are in the appendix

#### **Abstract**

This paper uses a robust method of spatial epidemiological analysis to assess the spatial growth rate of multiple lineages of SARS-CoV-2 in the local authority areas of England, September 2020–December 2021. Using the genomic surveillance records of the COVID-19 Genomics UK (COG-UK) Consortium, the analysis identifies a substantial (7.6-fold) difference in the average rate of spatial growth of 37 sample lineages, from the slowest (Delta AY.4.3) to the fastest (Omicron BA.1). Spatial growth of the Omicron (B.1.1.529 and BA) variant was found to be 2.81× faster than the Delta (B.1.617.2 and AY) variant and 3.76× faster than the Alpha (B.1.1.7 and Q) variant. In addition to AY.4.2 (a designated variant under investigation, VUI-21OCT-01), three Delta sublineages (AY.43, AY.98 and AY.120) were found to display a statistically faster rate of spatial growth than the parent lineage and would seem to merit further investigation. We suggest that the monitoring of spatial growth rates is a potentially valuable adjunct to routine assessments of the growth of emerging SARS-CoV-2 lineages in a defined population.

Kerry and steprint covo-19: England: been certified by peer review and should not be used to guide clinical practices.

# Introduction

Emerging lineages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have the potential to place significant pressure on public health systems due to increased infectivity, transmissibility, virulence, immune escape or other fitness advantage [1, 2]. Global genomic surveillance has identified >1,700 SARS-CoV-2 lineages since the beginning of the COVID-19 pandemic [3, 4], of which Alpha (B.1.1.7 and Q), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY) and Omicron (B.1.1.529 and BA) have been designated as variants of concern by the World Health Organization (WHO) on account of their global public health significance [5]. Additional lineages are currently classified on the basis of properties that are suggestive of an emerging (variants of interest) or possible future (variants under monitoring) risk to global public health [5]. The risk is well illustrated by the recent and rapid emergence of Omicron as the dominant variant in the United Kingdom, South Africa and the United States, among other countries, in late November and December 2021 [6–8].

One important epidemiological facet of an emerging SARS-CoV-2 lineage is its propensity to grow in a defined population [9]. There are well-established methods for assessing the rate of temporal growth by, for example, examining the trajectory of case doubling times or estimating the basic reproduction number,  $R_0$ , of the agent in question [10, 11]. Viewed from a geographical perspective, these measures are essentially aspatial in that they provide very little information on the geographical growth, or spatial expansion, of the associated infection wave. To extend the examination of SARS-CoV-2 growth rates into the spatial domain, the present paper applies a robust method of spatial epidemiological analysis that is known as the *swash-backwash model of the single epidemic wave* [12] to the genomic surveillance records of the COVID-19 Genomics UK (COG-UK) Consortium [13]. Using the spatial sequence of detection of sample variants as a proxy for the spatial wave front of infection, our examination yields estimates of the spatial growth rate of multiple SARS-CoV-2 lineages in the local authority areas of England, September 2020—December 2021.

For a total of 37 sample lineages under investigation, we present evidence of a substantial (7.6-fold) difference in the average rate of spatial growth, from the slowest (Delta

AY.4.3) to the fastest (Omicron BA.1). Whilst the overall results for the Alpha, Delta and Omicron variants are consistent with the documented growth advantages for these lineages, several emergent Delta sublineages (AY.4.2, AY.43, AY.98 and AY.120) are found to have had a statistically significant growth advantage over the parent lineage. To our knowledge, this is the first comparative study of the spatial growth rate of multiple emerging SARS-CoV-2 lineages at the national level. It is also the first report of a spatial growth advantage for the Delta AY.43, AY.98 and AY.120 lineages, and the first to document an apparently reduced spatial growth rate for a substantial number of other AY lineages that emerged in the spring and summer of 2021. We suggest that the monitoring of spatial growth rates is a potentially valuable adjunct to routine assessments of the growth of SARS-CoV-2 lineages in a defined population.

# Data and methods

Since September 2020, successive waves of SARS-CoV-2 infection with emerging lineages of the Alpha (September 2020 onset), Delta (March 2021 onset) and Omicron (November 2021 onset) variants have been recorded in England [14–16]. The weekly record of COVID-19 cases to mid-December 2021 is plotted in Figure 1A, whilst the underpinning sequence of variants is depicted in Figure 1B. As Figure 1B shows, Alpha, Delta and Omicron achieved the status of dominant variants in December 2020, May 2021 and December 2021, respectively.

#### FIGURE 1 NEAR HERE

# Data

We draw on the integrated national-level SARS-CoV-2 genomic surveillance records of the COVID-19 Genomics UK (COG-UK) Consortium [13]. Lineage counts by local authority area and week of sample collection for England were accessed from the COG-UK website [18] for a 68-week period, September 2020 (epidemiological week 36, ending 5 September) to December 2021 (epidemiological week 50, ending 18 December) (Figure 1B). The data set included geo-coded information on 979,075 SARS-CoV-2 samples assigned to the 309

Lower Tier Local Authority (LTLA) divisions of England. Here, we define the 309 LTLAs according to their most recent (May 2021) status. Information on the lineage of 20,655 samples (2.1%) was either suppressed (1,105) or not recorded (19,550). Of the remaining 958,420 samples, the majority (93.8%) were classified as belonging to the B.1.1.7 and Q (Alpha, 153,405 samples), B.1.617.2 and AY (Delta, 722,133 samples) and B.1.1.529 and BA (Omicron, 23,137 samples) lineages (Table 1). Samples belonging to these lineages form the basis of all our analysis.

# **TABLE 1 NEAR HERE**

#### Methods

To assess the spatial growth rate of a given SARS-CoV-2 lineage, we draw on the *swash-backwash model of the single epidemic wave* [12]. In essence, the model represents a spatial derivative of the generic *SIR* mass action models of infectious disease transmission [19]. Using the binary (presence/absence) of a disease, the model (i) allows the disaggregation of an infection wave into phases of spatial expansion and retreat and (ii) provides a means of measuring the phase transitions of geographical units from susceptible *S*, through infective *I* to recovered *R* status. See, for example, Smallman-Raynor and Cliff [20] and Smallman-Raynor, *et al.* [21].

Measuring the spatial growth rate

Full details of the modelling procedure are outlined by Cliff and Haggett [12]. For the purposes of the present analysis, we focus on the spatial expansion phase (that is, the change of state from S to I across a set geographical units) for a given SARS-CoV-2 lineage. Specifically, let the first week in which the lineage was detected in England be coded as t = 1. Subsequent weeks were then coded serially as t = 2, 3, ..., T, where T is the number of weekly periods from the beginning to the end of the detected occurrence of the lineage. For any given geographical unit, we refer to the first week in which the lineage was detected as the *leading edge* (LE) of the infection wave. The average time (in weeks) to the detection of

4

the lineage across the set of units can then be defined by a time-weighted mean,  $\bar{t}_{LE}$ , of the form

$$\bar{t}_{LE} = \frac{1}{N} \sum_{t=1}^{T} t n_t.$$
 (1)

Here,  $n_t$  is the number of units whose leading edge, LE, occurred in week t and  $N = \sum n_t$ . Formed in this manner, SARS-CoV-2 lineages with relatively high rates of spatial expansion (or rapidly developing LE) take on relatively low values of  $\bar{t}_{LE}$  (i.e. short average times to detection). Conversely, lineages with relatively low rates of spatial expansion (or slowly developing LE) take on relatively high values of  $\bar{t}_{LE}$  (i.e. long average times to detection).

# Application of the model

Equation (1) was used to estimate the spatial growth rate of sample SARS-CoV-2 lineages for which the earliest detection in England occurred in the time period covered by the dataset (September 2020–December 2021) and for which substantial geographical spread had been documented. To ensure the inclusion of sufficient observations for geographical analysis, the sample was limited to lineages that had been detected in at least one-third of the 309 LTLAs by December 2021. Based on these criteria, the sample consisted of 37 lineages. Summary details of the sample, including the number of LTLAs in which each lineage was detected, the total count of detections over the study period, and the earliest date of detection, are provided in Table 1.

For each lineage, equation (1) was fitted with t = 1 set to the week of earliest detection in Table 1. In the instance of Omicron, retrospective analysis has identified a lone detection of the BA.1 lineage in epidemiological week 43 of 2021 (week ending 30 October), four weeks prior to the subsequent detection and apparent onset of widespread transmission of the variant in epidemiological week 47 (week ending 27 November). For the purposes of the present analysis, we set week 47 as t = 1 for Omicron, but we also report the computed value of  $\bar{t}_{LE}$  based on the earlier detection in week 43. Finally, we exclude two LTLAs (City of London and Isles of Scilly) from all analysis on account of the suppression of lineage data due to their small populations. Data analysis was performed in Minitab<sup>®</sup>17 (Minitab Inc.,

Pennsylvania) and data mapping in QGIS 3.10.14-A Coruña (QGIS.org) using Local Authority Districts (May 2021) UK and Regions (December 2020) EN shapefiles from the Office for National Statistics (ONS) [22].

**Results** 

Table 1 confirms that the 37 sample lineages were geographically extensive in their transmission, with 29 having been detected in >150 LTLAs, 21 in >250 LTLAs, 16 in >300 LTLAs, and nine in the complete set of 307 LTLAs under examination. The majority (23) were associated with >1,000 detections, 13 with >10,000 detections and three with >100,000 detections. Delta (B.1.617.2 and AY) was the most common lineage (722,133 detections) and AY.4 the most common sublineage (547,403 detections), with AY lineages accounting for 33 of the spread events under examination. In turn, the majority of lineages emerged (as judged by the date of earliest detections) in the spring and summer of 2021, as the Delta infection wave was evolving both domestically and internationally.

Spatial growth curves and leading edge (*LE*) maps

The upper graphs in Figure 2 plot the count of LTLAs by week of earliest detection of the Alpha (B.1.1.7 and Q), Delta (B.1.617.2 and AY) and Omicron (B.1.1.529 and BA) variants, where weeks are indexed to the earliest detection of the respective variants (Table 1). The lower graphs are spatial growth curves, formed by replotting the information in the upper graphs as a cumulative proportion of LTLAs. Average curves for the set of sample lineages in Table 1 are shown for reference.

**FIGURE 2 NEAR HERE** 

Together, the graphs in Figure 2 portray the temporal development of the spatial leading edges (LE) for each variant. The geographical expression of these LE is captured by the choropleth maps in Figure 3 which plot the week of earliest detection of each variant in the set of LTLAs. The sequentially more rapid spatial growth of the variants (Alpha  $\rightarrow$  Delta  $\rightarrow$  Omicron) is evidenced by the sequentially steeper spatial growth curves (Figure 2) and the

6

sequentially shorter periods to earliest detection (Figure 3). The latter feature is emphasized when earliest detections are formed as regional averages in Figure 4.

#### FIGURE 3 NEAR HERE

#### FIGURE 4 NEAR HERE

# Rates of spatial growth $(\bar{t}_{LE})$

The right-hand column in Table 1 summarizes the results of the application of equation (1) to each of the sample lineages. Computed values of  $\bar{t}_{LE}$  and associated 95% confidence intervals (95% CI) are given, along with an overall average value of  $\bar{t}_{LE}$  for the entire sample. As noted above, lineages with relatively *high* rates of spatial expansion (or rapidly developing *LE*) are represented by relatively *low* values of  $\bar{t}_{LE}$  (i.e. short average times to detection), while lineages with relatively *low* rates of spatial expansion (or slowly developing *LE*) take on relatively *high* values of  $\bar{t}_{LE}$  (i.e. long average times to detection). In this manner, the table confirms the sequential increase in the spatial growth rate for Alpha, Delta and Omicron. On average, the earliest detection of the Alpha variant in a given LTLA occurred at  $\bar{t}_{LE} = 9.90$  (95% CI: 9.56, 10.23) weeks after the earliest sampled detection in England. This reduced to 7.40 (95% CI: 7.12, 7.68) weeks for Delta and 2.63 (95% CI: 2.56, 2.71) weeks for Omicron.

# Delta AY lineages

Figure 5 is based on the information in Table 1 and plots the values of  $\bar{t}_{LE}$  for B.1.617.2 and AY lineages in order, from the lowest (left, high values of  $\bar{t}_{LE}$ ) to the highest (right, low values of  $\bar{t}_{LE}$ ) rates of spatial growth. Values are plotted on an inverted vertical scale to facilitate interpretation. The average value of  $\bar{t}_{LE}$ , formed across the sample set of lineages in Table 1, is indicated for reference as are the  $\bar{t}_{LE}$  for the Alpha (B.1.1.7 and Q), Delta (B.1.617.2 and AY) and Omicron (B.1.1.529 and BA) variants. Spatial growth curves, formed in the manner of Figure 2, are plotted for a sample of 20 AY lineages with relatively high and low rates of spatial growth in Figure 6.

#### FIGURE 5 NEAR HERE

#### FIGURE 6 NEAR HERE

There is a 7.6-fold difference in the range of values of  $\bar{t}_{LE}$  in Figure 5, from Delta AY.4.3 with the lowest spatial growth rate (19.93 weeks) to Omicron with the highest (2.63 weeks). A group of four AY lineages (AY.4.2, AY.43, AY.98 and AY.120), first detected in the period from mid-May to mid-July 2021, are positioned between Delta and Omicron in Figure 5 and display rates of spatial growth that are significantly higher (as judged by 95% CI) than the aggregate rate for the Delta variant. In contrast, the overwhelming majority of AY lineages display statistically lower – in many instances substantially lower – spatial growth rates (as judged by 95% CI) than the aggregate rate for the Delta variant.

# **Discussion**

Recent experience has underscored the importance of the ongoing tracking, monitoring and analysis of emerging SARS-CoV-2 lineages with a view to mitigating the impacts of the COVID-19 pandemic [23]. We have used a robust model of spatial epidemiological analysis to estimate the rate of spatial growth of multiple lineages of the virus in England over a 68-week period, September 2020–December 2021. We have shown that the Alpha, Delta and Omicron variants took an average of 9.90 weeks, 7.40 weeks and 2.63 weeks, respectively, to reach the set of LTLAs under examination (Table 1 and Figure 5). Expressed in relative terms, the leading spatial edges were 1.34× faster (Delta vs. Alpha), 2.81× faster (Omicron vs. Delta), and 3.76× faster (Omicron vs. Alpha). Our estimates scale to the approximate length of time that Alpha (12 weeks), Delta (8 weeks) and Omicron (3 weeks) took to establish themselves as the dominant variants in England [18], and are consistent with evidence for the fitness advantage of Delta over Alpha and Omicron over Delta [11, 24, 25].

Of the 121 Delta AY lineages detected in England to December 2021 and included in the genomic surveillance records of the COG-UK Consortium, 33 lineages met the geographical criterion for inclusion in the current analysis. In interpreting the results for these lineages, we note that AY designations are phylogenetically defined and do not necessarily denote any fundamental biological differences between the lineages [26]. Moreover, results of the type documented in this paper are context dependent and cannot be interpreted as evidence of a change in biological transmissibility, immune escape or other fitness advantage.

Subject to these caveats, we have identified four AY lineages (AY.4.2, AY.43, AY.98 and AY.120) for which the rate of spatial growth exceeded the aggregate rate for the Delta variant. These lineages had been detected in all (AY.4.2, AY.43 and AY.98) or most (AY.120) of the local authority areas under investigation, and each had been associated with considerably more than 10,000 detections (Table 1). Table 2 summarizes the global status of these four lineages as of 9 January 2022. With the exception of the AY.43 lineage, which was prevalent in a number of European countries and associated with >267,000 detections worldwide, the majority of detections of these lineages originated from the United Kingdom.

#### **TABLE 2 NEAR HERE**

Our findings for the AY.4.2 and AY.4.3 lineages are consistent with their respective designations by the UK Health Security Agency as a distinct variant under investigation (VUI-21OCT-01) and a variant of concern [32, 33]. Preliminary investigations have indicated the AY.4.2 lineage to be associated with a higher growth rate and a higher household secondary attack rate, but with no significant reduction in vaccine effectiveness, as compared to the parent lineage [32, 34]. It remains to be established, however, whether the higher growth rate is due to enhanced transmissibility or is context-dependent [32, 35, 36]. Similarly, the status of the AY.43 lineage in terms of transmission advantage and/or immune escape remains to be determined, although further investigation is merited as new AY.43 sublineages have recently been reported from Brazil [37]. Finally, our identification of a rapid rate of spatial growth for the AY.98 and AY.120 lineages, approximating the estimated rates for AY.4.2 and AY.43, is noteworthy. Whilst very little has been documented on the epidemiological facets of these lineages, both have been identified in a number of countries in Europe and elsewhere (Table 2) and would seem to merit further investigation on the basis of the findings presented here.

With the foregoing exceptions, our analysis has shown that many emerging AY lineages in England in the spring and summer of 2021 were associated with spatial growth rates that were lower (in some instances, substantially lower) than the aggregate rate for the Delta variant (Table 1 and Figure 5). Multiple biological (e.g. reduced infectivity or

transmissibility) and contextual (e.g. progressive expansion of the national COVID-19 vaccination programme) factors may account for this observation. Importantly, there is no evidence of a temporal trend in the observed rates of spatial growth that would be suggestive of either (i) a biological selection pressure in favour of a growth advantage of emerging lineages or (ii) a progressive contextual effect in the form of, for example, increasing levels of vaccination coverage or natural immunity that would serve to retard growth rates.

Our estimates of  $\bar{t}_{LE}$  in Table 1 and Figure 5 are contingent on a range of public health interventions that operated to limit the spread of SARS-CoV-2. These interventions included: a tier system of local lockdown in October 2020; two periods of national lockdown (November–December 2020 and January–March 2021) and a phased lifting of national restrictions in the period to July 2021; a phased rollout of the national COVID-19 vaccination programme from December 2020; and the implementation of 'Plan B' control guidelines against the Omicron variant in December 2021 [38, 39]. Our results are also subject to the limitations of the available lineage data. Although the COG-UK Consortium genomic surveillance data are recognized for their extent and reliability [40], the data are formed as a sample of positive SARS-CoV-2 test results and are subject to the limitations and biases of sample data. In this context, we note that the cumulative coverage of the COG-UK records for England was estimated at 13.7% of people with positive SARS-CoV-2 test results to October 2021 [41]. Finally, our results are subject to the underpinning assumptions of the analytical procedure. In particular, the computation of  $\bar{t}_{LE}$  is dependent on the specification of the index week (i.e. the week that a given lineage was first detected in England) and the degree to which this reflects the date of actual emergence of the lineage in England. The extent to which the sample data accurately track the spatial expansion of the LE for a given lineage, the variable contributions of international travel- and community-related transmission to the development of the LE, and the geographical starting point(s) of a given lineage in the national transmission network, will also have influenced our results in unknown ways. For example, the early involvement and high degree of geographical connectivity of London and the South East may have served to accelerate the spatial transmission of the Alpha variant in the latter months of 2020 [14]. The observed rapid

spread of the Delta variant may reflect international importations and onwards transmission from multiple different geographical locations in the spring of 2021 [15, 42], whilst early cases of the Omicron variant were observed in highly connected regions at a time of reduced non-pharmaceutical interventions in November and December 2021 [43].

Further insights into the spatial growth and decay of SARS-CoV-2 lineages may be gained by application of the full swash-backwash model, but this is dependent on the substantial spatial retreat of any given lineage from the population. Here we note that, with the exception of AY.10 (last detected in July 2021) and AY.8 and Alpha (B.1.1.7 and Q) (both last detected in August/September 2021), there is evidence of the circulation of all the lineages included in Table 1 in the weeks to December 2021.

We have demonstrated, for the first time, a robust method for assessing and comparing the rate of spatial growth of multiple SARS-CoV-2 lineages in a set of geographical areas. We suggest that this approach represents a potentially valuable adjunct to routine assessments of the growth of emerging SARS-CoV-2 lineages in a defined population.

# References

- Dubey A, et al. (2021) Emerging SARS-CoV-2 variants: Genetic variability and clinical implications. Current Microbiology; 79(1):20. doi: 10.1007/s00284-021-02724-1.
- 2. Mukherjee R, Satardekar R (2021) Why are some coronavirus variants more infectious? *Journal of Biosciences*; 46(4):101. doi: 10.1007/s12038-021-00221-y.
- 3. O'Toole Á, *et al.* (2021) Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evolution*; 7(2):veab064. doi: 10.1093/ve/veab064.
- 4. GISAID (<a href="https://www.gisaid.org/hcov19-variants">https://www.gisaid.org/hcov19-variants</a>). Accessed 11 January 2022.
- World Health Organization, Tracking SARS-CoV-2 Variants
   (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). Accessed 11
   January 2022.
- 6. UK Health Security Agency, Variants of Concern or Under Investigation: Data up to 22

  December 2021 (<a href="https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-23-december-2021">https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-23-december-2021</a>). Accessed 11 January 2022.
- Centers for Disease Control and Prevention, COVID Data Tracker (<a href="https://covid.cdc.gov/covid-data-tracker/#nowcast-heading">https://covid.cdc.gov/covid-data-tracker/#nowcast-heading</a>). Accessed 11 January 2022.
- 8. Latif AA, *et al.* (2022) *BA.1 Lineage Report*. Outbreak.info (https://outbreak.info/situation-reports?pango=BA.1). Accessed 11 January 2022.
- 9. Ward T, *et al.* (2021) Growth, reproduction numbers and factors affecting the spread of SARS-CoV-2 novel variants of concern in the UK from October 2020 to July 2021: A modelling analysis. *BMJ Open*; 11(11):e056636. doi: 10.1136/bmjopen-2021-056636.
- 10. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 31. London: UK Health Security Agency, pp. 43.

- 11. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 33. London: UK Health Security Agency, pp. 42.
- 12. Cliff AD, Haggett P (2006) A swash-backwash model of the single epidemic wave. *Journal of Geographical Systems*; **8**: 227–252.
- 13. COVID-19 Genomics UK (COG-UK) Consortium (2020) An integrated national scale SARS-CoV-2 genomic surveillance network. *Lancet Microbe*; 1(3):e99-e100. doi: 10.1016/S2666-5247(20)30054-9.
- 14. Davies NG, *et al.* (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*; 372(6538):eabg3055. doi: 10.1126/science.abg3055.
- 15. Mishra S, *et al.* (2021) Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. *EClinicalMedicine*; 39:101064. doi: 10.1016/j.eclinm.2021.101064.
- 16. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing: Update on Hospitalisation and Vaccine Effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). London: UK Health Security Agency, pp. 17.
- 17. GOV.UK Coronavirus (COVID-19) in the UK (<a href="https://coronavirus.data.gov.uk/">https://coronavirus.data.gov.uk/</a>). Accessed 11 January 2022.
- COVID-19 Genomics UK (COG-UK) Consortium, COVID-19 Genomic Surveillance (<a href="https://covid19.sanger.ac.uk/lineages/raw">https://covid19.sanger.ac.uk/lineages/raw</a>). Accessed 11 January 2022.
- 19. Anderson RM, May R (1991) *Infectious Diseases of Humans: Dynamics and Control*. Oxford: Oxford University Press, pp. 757.
- Smallman-Raynor MR, Cliff AD (2014) Abrupt transition to heightened poliomyelitis epidemicity in England and Wales, 1947–1957, associated with a pronounced increase in the geographical rate of disease propagation. *Epidemiology and Infection*; 142: 577–591. doi: 10.1017/S0950268813001441.
- 21. Smallman-Raynor MR, Cliff AD, Stickler PJ. Meningococcal meningitis and coal mining in provincial England: Geographical perspectives on a major epidemic, 1929–

- 33. *Geographical Analysis*. Published online: 2 February 2021. doi: 10.1111/gean.12272.
- 22. Office for National Statistics (ONS) Open Geography portal (<a href="https://geoportal.statistics.gov.uk/">https://geoportal.statistics.gov.uk/</a>). Accessed 11 January 2022.
- 23. Angeletti S, *et al.* (2021) SARS-CoV-2 AY.4.2 variant circulating in Italy: Genomic preliminary insight. *Journal of Medical Virology*; 12:10.1002/jmv.27451. doi: 10.1002/jmv.27451.
- 24. He X, et al. (2021) The challenges of COVID-19 Delta variant: Prevention and vaccine development. MedComm (2020); 2: 846–854. doi: 10.1002/mco2.95.
- 25. Mahase E (2021) Covid-19: Do vaccines work against omicron-and other questions answered. *British Medical Journal*; 375:n3062. doi: 10.1136/bmj.n3062.
- Public Health England (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 23. London: Public Health England, pp. 61.
- 27. cov.lineages.org, PANGO Lineages: Latest Epidemiological Lineages of SARS-CoV-2 (<a href="https://cov-lineages.org/">https://cov-lineages.org/</a>). Accessed 11 January 2022.
- 28. Latif AA, *et al.* (2022) *AY.4.2 Lineage Report*. Outbreak.info (https://outbreak.info/situation-reports?pango=BA.1). Accessed 11 January 2022.
- 29. Latif AA, *et al.* (2022) *AY.43 Lineage Report*. Outbreak.info (https://outbreak.info/situation-reports?pango=BA.1). Accessed 11 January 2022.
- 30. Latif AA, et al. (2022) AY.98 Lineage Report. Outbreak.info (<a href="https://outbreak.info/situation-reports?pango=BA.1">https://outbreak.info/situation-reports?pango=BA.1</a>). Accessed 11 January 2022.
- 31. Latif AA, *et al.* (2022) *AY.120 Lineage Report*. Outbreak.info (https://outbreak.info/situation-reports?pango=BA.1). Accessed 11 January 2022.
- 32. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 27. London: UK Health Security Agency, pp. 63.

- 33. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 29. London: UK Health Security Agency, pp. 45.
- 34. Le Page M (2021) New variant gains ground. *New Scientist*; 252(3362):8. doi: 10.1016/S0262-4079(21)02091-1.
- 35. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 26. London: UK Health Security Agency, pp. 31.
- 36. UK Health Security Agency, Variants of Concern or Under Investigation: Data up to 5

  January 2022 (<a href="https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-7-january-2022">https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-7-january-2022</a>). Accessed 11 January 2022.
- 37. Lima ARJ, *et al.* (2021) SARS-CoV-2 genomic monitoring in the São Paulo State unveils new sublineages of the AY.43 strain. medRxiv doi: https://doi.org/10.1101/2021.11.29.21266819.
- 38. Brown J, Kirk-Wade E (2021) *Coronavirus: A History of 'Lockdown Laws' in England*. London: House of Commons Library, pp. 44.
- 39. NHS England, COVID-19 Vaccinations Archive (<a href="https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/covid-19-vaccinations-archive/">https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/covid-19-vaccinations-archive/</a>). Accessed 11 January 2022.
- 40. Robishaw JD, *et al.* (2021) Genomic surveillance to combat COVID-19: challenges and opportunities. *Lancet Microbe*; 2(9):e481-e484. doi: 10.1016/S2666-5247(21)00121-X.
- 41. COVID-19 Genomics UK (COG-UK) Consortium (2020), Coverage Reports (<a href="https://www.cogconsortium.uk/news-reports/coverage-reports/">https://www.cogconsortium.uk/news-reports/coverage-reports/</a>). Accessed 11 January 2022.
- 42. McCrone JT, *et al.* (2021) Context-specific emergence and growth of the SARS-CoV-2 Delta variant. medRxiv doi: 10.1101/2021.12.14.21267606.

43. UK Health Security Agency (2021) SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Variant of Concern: Omicron, VOC21NOV-01 (B.1.1.529) Technical Briefing 30. London: UK Health Security Agency, pp. 40.

# Appendix: The COVID-19 Genomics UK (COG-UK) Consortium

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: Samuel C Robson 13,84

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Thomas R Connor 11,74 and Nicholas J Loman 43

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation:

Tanya Golubchik 5

Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:

Rocio T Martinez Nunez 46

Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

David Bonsall 5

Funding acquisition, Leadership and supervision, Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation:

Andrew Rambaut 104

Funding acquisition, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Luke B Snell 12

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Software and analysis tools, and Visualisation:

Rich Livett 116

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, and Samples and logistics:

Catherine Ludden 20,70

Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis:

Sally Corden 74 and Eleni Nastouli 96, 95, 30

Funding acquisition, Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools:

Gaia Nebbia 12

Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:

Ian Johnston 116

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis:

Katrina Lythgoe 5, M. Estee Torok 19, 20 and Ian G Goodfellow 24

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Visualisation:

Jacqui A Prieto 97,82 and Kordo Saeed 97,83

Leadership and supervision, Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools:

David K Jackson 116

Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:

Catherine Houlihan 96, 94

Leadership and supervision, Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation:

Dan Frampton 94,95

Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

William L Hamilton 19 and Adam A Witney 41

Funding acquisition, Samples and logistics, Sequencing and analysis, and Visualisation: Giselda Bucca <sup>101</sup>

Funding acquisition, Leadership and supervision, Metadata curation, and Project administration: Cassie F Pope 40,41

Funding acquisition, Leadership and supervision, Metadata curation, and Samples and logistics: Catherine Moore  $^{74}$ 

Funding acquisition, Leadership and supervision, Metadata curation, and Sequencing and analysis: Emma C Thomson <sup>53</sup>

Funding acquisition, Leadership and supervision, Project administration, and Samples and logistics:

Ewan M Harrison 116, 102

Funding acquisition, Leadership and supervision, Sequencing and analysis, and Visualisation: Colin P Smith 101

Leadership and supervision, Metadata curation, Project administration, and Sequencing and analysis:

Fiona Rogan 77

Leadership and supervision, Metadata curation, Project administration, and Samples and logistics: Shaun M Beckwith <sup>6</sup>, Abigail Murray <sup>6</sup>, Dawn Singleton <sup>6</sup>, Kirstine Eastick <sup>37</sup>, Liz A Sheridan <sup>98</sup>, Paul Randell <sup>99</sup>, Leigh M Jackson <sup>105</sup>, Cristina V Ariani <sup>116</sup> and Sónia Gonçalves <sup>116</sup>

Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis:

Derek J Fairley 3,77, Matthew W Loose 18 and Joanne Watkins 74

Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation:

Samuel Moses 25, 106

Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools:

Sam Nicholls <sup>43</sup>, Matthew Bull <sup>74</sup> and Roberto Amato <sup>116</sup>

Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:

Darren L Smith 36, 65, 66

Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation:

David M Aanensen 14, 116 and Jeffrey C Barrett 116

Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis:

Dinesh Aggarwal <sup>20, 116, 70</sup>, James G Shepherd <sup>53</sup>, Martin D Curran <sup>71</sup> and Surendra Parmar <sup>71</sup>

Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools:

Matthew D Parker 109

Metadata curation, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Catryn Williams 74

Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:

Sharon Glaysher 68

Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation:

Anthony P Underwood <sup>14, 116</sup>, Matthew Bashton <sup>36, 65</sup>, Nicole Pacchiarini <sup>74</sup>, Katie F Loveson <sup>84</sup> and Matthew Byott <sup>95, 96</sup>

Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation:

Alessandro M Carabelli 20

Funding acquisition, Leadership and supervision, and Metadata curation:

Kate E Templeton 56, 104

Funding acquisition, Leadership and supervision, and Project administration:

Thushan I de Silva 109, Dennis Wang 109, Cordelia F Langford 116 and John Sillitoe 116

Funding acquisition, Leadership and supervision, and Samples and logistics:

Rory N Gunson 55

Funding acquisition, Leadership and supervision, and Sequencing and analysis:

Simon Cottrell 74, Justin O'Grady 75, 103 and Dominic Kwiatkowski 116, 108

#### Leadership and supervision, Metadata curation, and Project administration:

Patrick J Lillie 37

# Leadership and supervision, Metadata curation, and Samples and logistics:

Nicholas Cortes  $^{33}$ , Nathan Moore  $^{33}$ , Claire Thomas  $^{33}$ , Phillipa J Burns  $^{37}$ , Tabitha W Mahungu  $^{80}$  and Steven Liggett  $^{86}$ 

## Leadership and supervision, Metadata curation, and Sequencing and analysis:

Angela H Beckett 13,81 and Matthew TG Holden 73

# Leadership and supervision, Project administration, and Samples and logistics:

Lisa J Levett <sup>34</sup>, Husam Osman <sup>70, 35</sup> and Mohammed O Hassan-Ibrahim <sup>99</sup>

#### Leadership and supervision, Project administration, and Sequencing and analysis:

David A Simpson 77

#### Leadership and supervision, Samples and logistics, and Sequencing and analysis:

Meera Chand <sup>72</sup>, Ravi K Gupta <sup>102</sup>, Alistair C Darby <sup>107</sup> and Steve Paterson <sup>107</sup>

#### Leadership and supervision, Sequencing and analysis, and Software and analysis tools:

Oliver G Pybus <sup>23</sup>, Erik M Volz <sup>39</sup>, Daniela de Angelis <sup>52</sup>, David L Robertson <sup>53</sup>, Andrew J Page <sup>75</sup> and Inigo Martincorena <sup>116</sup>

#### Leadership and supervision, Sequencing and analysis, and Visualisation:

Louise Aigrain <sup>116</sup> and Andrew R Bassett <sup>116</sup>

#### Metadata curation, Project administration, and Samples and logistics:

Nick Wong 50, Yusri Taha 89, Michelle J Erkiert 99 and Michael H Spencer Chapman 116, 102

#### Metadata curation, Project administration, and Sequencing and analysis:

Rebecca Dewar <sup>56</sup> and Martin P McHugh <sup>56, 111</sup>

#### Metadata curation, Project administration, and Software and analysis tools:

Siddharth Mookerjee 38,57

#### Metadata curation, Project administration, and Visualisation:

Stephen Aplin <sup>97</sup>, Matthew Harvey <sup>97</sup>, Thea Sass <sup>97</sup>, Helen Umpleby <sup>97</sup> and Helen Wheeler <sup>97</sup>

#### Metadata curation, Samples and logistics, and Sequencing and analysis:

James P McKenna <sup>3</sup>, Ben Warne <sup>9</sup>, Joshua F Taylor <sup>22</sup>, Yasmin Chaudhry <sup>24</sup>, Rhys Izuagbe <sup>24</sup>, Aminu S Jahun <sup>24</sup>, Gregory R Young <sup>36, 65</sup>, Claire McMurray <sup>43</sup>, Clare M McCann <sup>65, 66</sup>, Andrew Nelson <sup>65, 66</sup> and Scott Elliott <sup>68</sup>

# Metadata curation, Samples and logistics, and Visualisation:

Hannah Lowe <sup>25</sup>

#### Metadata curation, Sequencing and analysis, and Software and analysis tools:

Anna Price 11, Matthew R Crown 65, Sara Rey 74, Sunando Roy 96 and Ben Temperton 105

#### Metadata curation, Sequencing and analysis, and Visualisation:

Sharif Shaaban 73 and Andrew R Hesketh 101

#### Project administration, Samples and logistics, and Sequencing and analysis:

Kenneth G Laing 41, Irene M Monahan 41 and Judith Heaney 95, 96, 34

#### Project administration, Samples and logistics, and Visualisation:

Emanuela Pelosi <sup>97</sup>, Siona Silviera <sup>97</sup> and Eleri Wilson-Davies <sup>97</sup>

# Samples and logistics, Software and analysis tools, and Visualisation:

Helen Fryer <sup>5</sup>

#### Sequencing and analysis, Software and analysis tools, and Visualization:

Helen Adams <sup>4</sup>, Louis du Plessis <sup>23</sup>, Rob Johnson <sup>39</sup>, William T Harvey <sup>53, 42</sup>, Joseph Hughes <sup>53</sup>, Richard J Orton <sup>53</sup>, Lewis G Spurgin <sup>59</sup>, Yann Bourgeois <sup>81</sup>, Chris Ruis <sup>102</sup>, Áine O'Toole <sup>104</sup>, Marina Gourtovaia <sup>116</sup> and Theo Sanderson <sup>116</sup>

# Funding acquisition, and Leadership and supervision:

Christophe Fraser <sup>5</sup>, Jonathan Edgeworth <sup>12</sup>, Judith Breuer <sup>96, 29</sup>, Stephen L Michell <sup>105</sup> and John A Todd <sup>115</sup>

#### Funding acquisition, and Project administration:

Michaela John <sup>10</sup> and David Buck <sup>115</sup>

# Leadership and supervision, and Metadata curation:

Kavitha Gajee <sup>37</sup> and Gemma L Kay <sup>75</sup>

#### Leadership and supervision, and Project administration:

Sharon J Peacock <sup>20, 70</sup> and David Heyburn <sup>74</sup>

#### **Leadership and supervision, and Samples and logistics:**

Katie Kitchman <sup>37</sup>, Alan McNally <sup>43, 93</sup>, David T Pritchard <sup>50</sup>, Samir Dervisevic <sup>58</sup>, Peter Muir <sup>70</sup>, Esther Robinson <sup>70, 35</sup>, Barry B Vipond <sup>70</sup>, Newara A Ramadan <sup>78</sup>, Christopher Jeanes <sup>90</sup>, Danni Weldon <sup>116</sup>, Jana Catalan <sup>118</sup> and Neil Jones <sup>118</sup>

#### Leadership and supervision, and Sequencing and analysis:

Ana da Silva Filipe  $^{53}$ , Chris Williams  $^{74}$ , Marc Fuchs  $^{77}$ , Julia Miskelly  $^{77}$ , Aaron R Jeffries  $^{105}$ , Karen Oliver  $^{116}$  and Naomi R Park  $^{116}$ 

#### Metadata curation, and Samples and logistics:

Amy Ash <sup>1</sup>, Cherian Koshy <sup>1</sup>, Magdalena Barrow <sup>7</sup>, Sarah L Buchan <sup>7</sup>, Anna Mantzouratou <sup>7</sup>, Gemma Clark <sup>15</sup>, Christopher W Holmes <sup>16</sup>, Sharon Campbell <sup>17</sup>, Thomas Davis <sup>21</sup>, Ngee Keong Tan <sup>22</sup>, Julianne R Brown <sup>29</sup>, Kathryn A Harris <sup>29, 2</sup>, Stephen P Kidd <sup>33</sup>, Paul R Grant <sup>34</sup>, Li Xu-McCrae <sup>35</sup>, Alison Cox <sup>38, 63</sup>, Pinglawathee Madona <sup>38, 63</sup>, Marcus Pond <sup>38, 63</sup>, Paul A Randell <sup>38, 63</sup>, Karen T Withell <sup>48</sup>, Cheryl Williams <sup>51</sup>, Clive Graham <sup>60</sup>, Rebecca Denton-Smith <sup>62</sup>, Emma Swindells <sup>62</sup>, Robyn Turnbull <sup>62</sup>, Tim J Sloan <sup>67</sup>, Andrew Bosworth <sup>70, 35</sup>, Stephanie Hutchings <sup>70</sup>, Hannah M Pymont <sup>70</sup>, Anna Casey <sup>76</sup>, Liz Ratcliffe <sup>76</sup>, Christopher R Jones <sup>79, 105</sup>, Bridget A Knight <sup>79, 105</sup>, Tanzina Haque <sup>80</sup>, Jennifer Hart <sup>80</sup>, Dianne Irish-Tavares <sup>80</sup>, Eric Witele <sup>80</sup>, Craig Mower <sup>86</sup>, Louisa K Watson <sup>86</sup>, Jennifer Collins <sup>89</sup>, Gary Eltringham <sup>89</sup>, Dorian Crudgington <sup>98</sup>, Ben Macklin <sup>98</sup>, Miren Iturriza-Gomara <sup>107</sup>, Anita O Lucaci <sup>107</sup> and Patrick C McClure <sup>113</sup>

#### Metadata curation, and Sequencing and analysis:

Matthew Carlile <sup>18</sup>, Nadine Holmes <sup>18</sup>, Christopher Moore <sup>18</sup>, Nathaniel Storey <sup>29</sup>, Stefan Rooke <sup>73</sup>, Gonzalo Yebra <sup>73</sup>, Noel Craine <sup>74</sup>, Malorie Perry <sup>74</sup>, Nabil-Fareed Alikhan <sup>75</sup>, Stephen Bridgett <sup>77</sup>, Kate F Cook <sup>84</sup>, Christopher Fearn <sup>84</sup>, Salman Goudarzi <sup>84</sup>, Ronan A Lyons <sup>88</sup>, Thomas Williams <sup>104</sup>, Sam T Haldenby <sup>107</sup>, Jillian Durham <sup>116</sup> and Steven Leonard <sup>116</sup>

#### Metadata curation, and Software and analysis tools:

Robert M Davies 116

# **Project administration, and Samples and logistics:**

Rahul Batra <sup>12</sup>, Beth Blane <sup>20</sup>, Moira J Spyer <sup>30, 95, 96</sup>, Perminder Smith <sup>32, 112</sup>, Mehmet Yavus <sup>85, 109</sup>, Rachel J Williams <sup>96</sup>, Adhyana IK Mahanama <sup>97</sup>, Buddhini Samaraweera <sup>97</sup>, Sophia T Girgis <sup>102</sup>, Samantha E Hansford <sup>109</sup>, Angie Green <sup>115</sup>, Charlotte Beaver <sup>116</sup>, Katherine L Bellis <sup>116, 102</sup>, Matthew J Dorman <sup>116</sup>, Sally Kay <sup>116</sup>, Liam Prestwood <sup>116</sup> and Shavanthi Rajatileka <sup>116</sup>

#### Project administration, and Sequencing and analysis:

Joshua Quick 43

#### Project administration, and Software and analysis tools:

Radoslaw Poplawski 43

#### Samples and logistics, and Sequencing and analysis:

Nicola Reynolds <sup>8</sup>, Andrew Mack <sup>11</sup>, Arthur Morriss <sup>11</sup>, Thomas Whalley <sup>11</sup>, Bindi Patel <sup>12</sup>, Iliana Georgana <sup>24</sup>, Myra Hosmillo <sup>24</sup>, Malte L Pinckert <sup>24</sup>, Joanne Stockton <sup>43</sup>, John H Henderson <sup>65</sup>, Amy Hollis <sup>65</sup>, William Stanley <sup>65</sup>, Wen C Yew <sup>65</sup>, Richard Myers <sup>72</sup>, Alicia Thornton <sup>72</sup>, Alexander Adams <sup>74</sup>, Tara Annett <sup>74</sup>, Hibo Asad <sup>74</sup>, Alec Birchley <sup>74</sup>, Jason Coombes <sup>74</sup>, Johnathan M Evans <sup>74</sup>, Laia Fina <sup>74</sup>, Bree Gatica-Wilcox <sup>74</sup>, Lauren Gilbert <sup>74</sup>, Lee Graham <sup>74</sup>, Jessica Hey <sup>74</sup>, Ember Hilvers <sup>74</sup>, Sophie Jones <sup>74</sup>, Hannah Jones <sup>74</sup>, Sara Kumziene-Summerhayes <sup>74</sup>, Caoimhe McKerr <sup>74</sup>, Jessica Powell <sup>74</sup>, Georgia Pugh <sup>74</sup>, Sarah Taylor <sup>74</sup>, Alexander J Trotter <sup>75</sup>, Charlotte A Williams <sup>96</sup>, Leanne M Kermack <sup>102</sup>, Benjamin H Foulkes <sup>109</sup>, Marta Gallis <sup>109</sup>, Hailey R Hornsby <sup>109</sup>, Stavroula F Louka <sup>109</sup>, Manoj Pohare <sup>109</sup>, Paige Wolverson <sup>109</sup>, Peijun Zhang <sup>109</sup>, George MacIntyre-Cockett <sup>115</sup>, Amy Trebes <sup>115</sup>, Robin J Moll <sup>116</sup>, Lynne Ferguson <sup>117</sup>, Emily J Goldstein <sup>117</sup>, Alasdair Maclean <sup>117</sup> and Rachael Tomb <sup>117</sup>

# Samples and logistics, and Software and analysis tools:

Igor Starinskij 53

#### Sequencing and analysis, and Software and analysis tools:

Laura Thomson <sup>5</sup>, Joel Southgate <sup>11, 74</sup>, Moritz UG Kraemer <sup>23</sup>, Jayna Raghwani <sup>23</sup>, Alex E Zarebski <sup>23</sup>, Olivia Boyd <sup>39</sup>, Lily Geidelberg <sup>39</sup>, Chris J Illingworth <sup>52</sup>, Chris Jackson <sup>52</sup>, David Pascall <sup>52</sup>, Sreenu Vattipally <sup>53</sup>, Timothy M Freeman <sup>109</sup>, Sharon N Hsu <sup>109</sup>, Benjamin B Lindsey <sup>109</sup>, Keith James <sup>116</sup>, Kevin Lewis <sup>116</sup>, Gerry Tonkin-Hill <sup>116</sup> and Jaime M Tovar-Corona <sup>116</sup>

#### Sequencing and analysis, and Visualisation:

MacGregor Cox 20

#### Software and analysis tools, and Visualisation:

Khalil Abudahab <sup>14, 116</sup>, Mirko Menegazzo <sup>14</sup>, Ben EW Taylor MEng <sup>14, 116</sup>, Corin A Yeats <sup>14</sup>, Afrida Mukaddas <sup>53</sup>, Derek W Wright <sup>53</sup>, Leonardo de Oliveira Martins <sup>75</sup>, Rachel Colquhoun <sup>104</sup>, Verity Hill <sup>104</sup>, Ben Jackson <sup>104</sup>, JT McCrone <sup>104</sup>, Nathan Medd <sup>104</sup>, Emily Scher <sup>104</sup> and Jon-Paul Keatley <sup>116</sup>

#### Leadership and supervision:

Tanya Curran <sup>3</sup>, Sian Morgan <sup>10</sup>, Patrick Maxwell <sup>20</sup>, Ken Smith <sup>20</sup>, Sahar Eldirdiri <sup>21</sup>, Anita Kenyon <sup>21</sup>, Alison H Holmes <sup>38, 57</sup>, James R Price <sup>38, 57</sup>, Tim Wyatt <sup>69</sup>, Alison E Mather <sup>75</sup>, Timofey Skvortsov <sup>77</sup> and John A Hartley <sup>96</sup>

#### Metadata curation:

Martyn Guest <sup>11</sup>, Christine Kitchen <sup>11</sup>, Ian Merrick <sup>11</sup>, Robert Munn <sup>11</sup>, Beatrice Bertolusso <sup>33</sup>, Jessica Lynch <sup>33</sup>, Gabrielle Vernet <sup>33</sup>, Stuart Kirk <sup>34</sup>, Elizabeth Wastnedge <sup>56</sup>, Rachael Stanley <sup>58</sup>, Giles Idle <sup>64</sup>, Declan T Bradley <sup>69,77</sup>, Jennifer Poyner <sup>79</sup> and Matilde Mori <sup>110</sup>

#### **Project administration:**

Owen Jones <sup>11</sup>, Victoria Wright <sup>18</sup>, Ellena Brooks <sup>20</sup>, Carol M Churcher <sup>20</sup>, Mireille Fragakis <sup>20</sup>, Katerina Galai <sup>20, 70</sup>, Andrew Jermy <sup>20</sup>, Sarah Judges <sup>20</sup>, Georgina M McManus <sup>20</sup>, Kim S Smith <sup>20</sup>, Elaine Westwick <sup>20</sup>, Stephen W Attwood <sup>23</sup>, Frances Bolt <sup>38, 57</sup>, Alisha Davies <sup>74</sup>, Elen De Lacy <sup>74</sup>, Fatima Downing <sup>74</sup>, Sue Edwards <sup>74</sup>, Lizzie Meadows <sup>75</sup>, Sarah Jeremiah <sup>97</sup>, Nikki Smith <sup>109</sup> and Luke Foulser <sup>116</sup>

#### Samples and logistics:

Themoula Charalampous 12, 46, Amita Patel 12, Louise Berry 15, Tim Boswell 15, Vicki M Fleming 15, Hannah C Howson-Wells <sup>15</sup>, Amelia Joseph <sup>15</sup>, Manjinder Khakh <sup>15</sup>, Michelle M Lister <sup>15</sup>, Paul W Bird <sup>16</sup>, Karlie Fallon <sup>16</sup>, Thomas Helmer <sup>16</sup>, Claire L McMurray <sup>16</sup>, Mina Odedra <sup>16</sup>, Jessica Shaw <sup>16</sup>, Julian W Tang <sup>16</sup>, Nicholas J Willford <sup>16</sup>, Victoria Blakey <sup>17</sup>, Veena Raviprakash <sup>17</sup>, Nicola Sheriff <sup>17</sup>, Lesley-Anne Williams <sup>17</sup>, Theresa Feltwell <sup>20</sup>, Luke Bedford <sup>26</sup>, James S Cargill <sup>27</sup>, Warwick Hughes <sup>27</sup>, Jonathan Moore <sup>28</sup>, Susanne Stonehouse <sup>28</sup>, Laura Atkinson <sup>29</sup>, Jack CD Lee <sup>29</sup>, Dr Divya Shah <sup>29</sup>, Adela Alcolea-Medina <sup>32, 112</sup>, Natasha Ohemeng-Kumi <sup>32, 112</sup>, John Ramble <sup>32, 112</sup>, Jasveen Sehmi <sup>32, 112</sup>, Rebecca Williams <sup>33</sup>, Wendy Chatterton <sup>34</sup>, Monika Pusok <sup>34</sup>, William Everson <sup>37</sup>, Anibolina Castigador <sup>44</sup>, Emily Macnaughton 44, Kate El Bouzidi 45, Temi Lampejo 45, Malur Sudhanva 45, Cassie Breen 47, Graciela Sluga 48, Shazaad SY Ahmad 49, 70, Ryan P George 49, Nicholas W Machin 49, 70, Debbie Binns 50, Victoria James <sup>50</sup>, Rachel Blacow <sup>55</sup>, Lindsay Coupland <sup>58</sup>, Louise Smith <sup>59</sup>, Edward Barton <sup>60</sup>, Debra Padgett <sup>60</sup>, Garren Scott <sup>60</sup>, Aidan Cross <sup>61</sup>, Mariyam Mirfenderesky <sup>61</sup>, Jane Greenaway <sup>62</sup>, Kevin Cole <sup>64</sup>, Phillip Clarke <sup>67</sup>, Nichola Duckworth <sup>67</sup>, Sarah Walsh <sup>67</sup>, Kelly Bicknell <sup>68</sup>, Robert Impey <sup>68</sup>, Sarah Wyllie <sup>68</sup>, Richard Hopes <sup>70</sup>, Chloe Bishop <sup>72</sup>, Vicki Chalker <sup>72</sup>, Ian Harrison <sup>72</sup>, Laura Gifford <sup>74</sup>, Zoltan Molnar <sup>77</sup>, Cressida Auckland 79, Cariad Evans 85, 109, Kate Johnson 85, 109, David G Partridge 85, 109, Mohammad Raza <sup>85, 109</sup>, Paul Baker <sup>86</sup>, Stephen Bonner <sup>86</sup>, Sarah Essex <sup>86</sup>, Leanne J Murray <sup>86</sup>, Andrew I Lawton <sup>87</sup>, Shirelle Burton-Fanning 89, Brendan Al Payne 89, Sheila Waugh 89, Andrea N Gomes 91, Maimuna Kimuli <sup>91</sup>, Darren R Murray <sup>91</sup>, Paula Ashfield <sup>92</sup>, Donald Dobie <sup>92</sup>, Fiona Ashford <sup>93</sup>, Angus Best <sup>93</sup>, Liam Crawford <sup>93</sup>, Nicola Cumley <sup>93</sup>, Megan Mayhew <sup>93</sup>, Oliver Megram <sup>93</sup>, Jeremy Mirza <sup>93</sup>, Emma Moles-Garcia 93, Benita Percival 93, Megan Driscoll 96, Leah Ensell 96, Helen L Lowe 96, Laurentiu Maftei 96, Matteo Mondani 96, Nicola J Chaloner 99, Benjamin J Cogger 99, Lisa J Easton 99, Hannah Huckson 99, Jonathan Lewis 99, Sarah Lowdon 99, Cassandra S Malone 99, Florence Munemo 99, Manasa Mutingwende <sup>99</sup>, Roberto Nicodemi <sup>99</sup>, Olga Podplomyk <sup>99</sup>, Thomas Somassa <sup>99</sup>, Andrew Beggs <sup>100</sup>, Alex Richter <sup>100</sup>, Claire Cormie <sup>102</sup>, Joana Dias <sup>102</sup>, Sally Forrest <sup>102</sup>, Ellen E Higginson <sup>102</sup>, Mailis Maes <sup>102</sup>, Jamie Young <sup>102</sup>, Rose K Davidson <sup>103</sup>, Kathryn A Jackson <sup>107</sup>, Lance Turtle <sup>107</sup>, Alexander J Keeley 109, Jonathan Ball 113, Timothy Byaruhanga 113, Joseph G Chappell 113, Jayasree Dey 113, Jack D Hill 113, Emily J Park <sup>113</sup>, Arezou Fanaie <sup>114</sup>, Rachel A Hilson <sup>114</sup>, Geraldine Yaze <sup>114</sup> and Stephanie Lo <sup>116</sup>

# Sequencing and analysis:

Safiah Afifi <sup>10</sup>, Robert Beer <sup>10</sup>, Joshua Maksimovic <sup>10</sup>, Kathryn McCluggage <sup>10</sup>, Karla Spellman <sup>10</sup>, Catherine Bresner <sup>11</sup>, William Fuller <sup>11</sup>, Angela Marchbank <sup>11</sup>, Trudy Workman <sup>11</sup>, Ekaterina Shelest <sup>13</sup>, <sup>81</sup>, Johnny Debebe <sup>18</sup>, Fei Sang <sup>18</sup>, Marina Escalera Zamudio <sup>23</sup>, Sarah Francois <sup>23</sup>, Bernardo Gutierrez <sup>23</sup>, Tetyana I Vasylyeva <sup>23</sup>, Flavia Flaviani <sup>31</sup>, Manon Ragonnet-Cronin <sup>39</sup>, Katherine L Smollett <sup>42</sup>, Alice Broos <sup>53</sup>, Daniel Mair <sup>53</sup>, Jenna Nichols <sup>53</sup>, Kyriaki Nomikou <sup>53</sup>, Lily Tong <sup>53</sup>, loulia Tsatsani <sup>53</sup>, Sarah

O'Brien <sup>54</sup>, Steven Rushton <sup>54</sup>, Roy Sanderson <sup>54</sup>, Jon Perkins <sup>55</sup>, Seb Cotton <sup>56</sup>, Abbie Gallagher <sup>56</sup>, Elias Allara <sup>70, 102</sup>, Clare Pearson <sup>70, 102</sup>, David Bibby <sup>72</sup>, Gavin Dabrera <sup>72</sup>, Nicholas Ellaby <sup>72</sup>, Eileen Gallagher <sup>72</sup>, Jonathan Hubb <sup>72</sup>, Angie Lackenby <sup>72</sup>, David Lee <sup>72</sup>, Nikos Manesis <sup>72</sup>, Tamyo Mbisa <sup>72</sup>, Steven Platt <sup>72</sup>, Katherine A Twohig <sup>72</sup>, Mari Morgan <sup>74</sup>, Alp Aydin <sup>75</sup>, David J Baker <sup>75</sup>, Ebenezer Foster-Nyarko <sup>75</sup>, Sophie J Prosolek <sup>75</sup>, Steven Rudder <sup>75</sup>, Chris Baxter <sup>77</sup>, Sílvia F Carvalho <sup>77</sup>, Deborah Lavin <sup>77</sup>, Arun Mariappan <sup>77</sup>, Clara Radulescu <sup>77</sup>, Aditi Singh <sup>77</sup>, Miao Tang <sup>77</sup>, Helen Morcrette <sup>79</sup>, Nadua Bayzid <sup>96</sup>, Marius Cotic <sup>96</sup>, Carlos E Balcazar <sup>104</sup>, Michael D Gallagher <sup>104</sup>, Daniel Maloney <sup>104</sup>, Thomas D Stanton <sup>104</sup>, Kathleen A Williamson <sup>104</sup>, Robin Manley <sup>105</sup>, Michelle L Michelsen <sup>105</sup>, Christine M Sambles <sup>105</sup>, David J Studholme <sup>105</sup>, Joanna Warwick-Dugdale <sup>105</sup>, Richard Eccles <sup>107</sup>, Matthew Gemmell <sup>107</sup>, Richard Gregory <sup>107</sup>, Margaret Hughes <sup>107</sup>, Charlotte Nelson <sup>107</sup>, Lucille Rainbow <sup>107</sup>, Edith E Vamos <sup>107</sup>, Hermione J Webster <sup>107</sup>, Mark Whitehead <sup>107</sup>, Claudia Wierzbicki <sup>107</sup>, Adrienn Angyal <sup>109</sup>, Luke R Green <sup>109</sup>, Max Whiteley <sup>109</sup>, Emma Betteridge <sup>116</sup>, Iraad F Bronner <sup>116</sup>, Ben W Farr <sup>116</sup>, Scott Goodwin <sup>116</sup>, Stefanie V Lensing <sup>116</sup>, Shane A McCarthy <sup>116, 102</sup>, Michael A Quail <sup>116</sup>, Diana Rajan <sup>116</sup>, Nicholas M Redshaw <sup>116</sup>, Carol Scott <sup>116</sup>, Lesley Shirley <sup>116</sup> and Scott AJ Thurston <sup>116</sup>

#### Software and analysis tools:

Will Rowe  $^{43}$ , Amy Gaskin  $^{74}$ , Thanh Le-Viet  $^{75}$ , James Bonfield  $^{116}$ , Jennifier Liddle  $^{116}$  and Andrew Whitwham  $^{116}$ 

1 Barking, Havering and Redbridge University Hospitals NHS Trust, 2 Barts Health NHS Trust, 3 Belfast Health & Social Care Trust, 4 Betsi Cadwaladr University Health Board, 5 Big Data Institute, Nuffield Department of Medicine, University of Oxford, 6 Blackpool Teaching Hospitals NHS Foundation Trust, 7 Bournemouth University, 8 Cambridge Stem Cell Institute, University of Cambridge, 9 Cambridge University Hospitals NHS Foundation Trust, 10 Cardiff and Vale University Health Board, 11 Cardiff University, 12 Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 13 Centre for Enzyme Innovation, University of Portsmouth, 14 Centre for Genomic Pathogen Surveillance, University of Oxford, 15 Clinical Microbiology Department, Queens Medical Centre, Nottingham University Hospitals NHS Trust, 16 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 17 County Durham and Darlington NHS Foundation Trust, 18 Deep Seq, School of Life Sciences, Queens Medical Centre, University of Nottingham, 19 Department of Infectious Diseases and Microbiology, Cambridge University Hospitals NHS Foundation Trust, 20 Department of Medicine, University of Cambridge, 21 Department of Microbiology, Kettering General Hospital, 22 Department of Microbiology, South West London Pathology, 23 Department of Zoology, University of Oxford, 24 Division of Virology, Department of Pathology, University of Cambridge, 25 East Kent Hospitals University NHS Foundation Trust, 26 East Suffolk and North Essex NHS Foundation Trust, 27 East Sussex Healthcare NHS Trust, 28 Gateshead Health NHS Foundation Trust, 29 Great Ormond Street Hospital for Children NHS Foundation Trust, 30 Great Ormond Street Institute of Child Health (GOS ICH), University College London (UCL), 31 Guy's and St. Thomas' Biomedical Research Centre, 32 Guy's and St. Thomas' NHS Foundation Trust, 33 Hampshire Hospitals NHS Foundation Trust, 34 Health Services Laboratories, 35 Heartlands Hospital, Birmingham, 36 Hub for Biotechnology in the Built Environment, Northumbria University, 37 Hull University Teaching Hospitals NHS Trust, 38 Imperial College Healthcare NHS Trust, 39 Imperial College London, 40 Infection Care Group, St George's University Hospitals NHS Foundation Trust, 41 Institute for Infection and Immunity, St George's University of London, 42 Institute of Biodiversity, Animal Health & Comparative Medicine, 43 Institute of Microbiology and Infection, University of Birmingham, 44 Isle of Wight NHS Trust, 45 King's College Hospital NHS Foundation Trust, 46 King's College London, 47 Liverpool Clinical Laboratories, 48 Maidstone and Tunbridge Wells NHS Trust, 49 Manchester University NHS Foundation Trust, 50 Microbiology Department, Buckinghamshire Healthcare NHS Trust, 51 Microbiology, Royal Oldham Hospital, 52 MRC Biostatistics Unit, University of Cambridge, 53 MRC-University of Glasgow Centre for Virus Research, 54 Newcastle University, 55 NHS Greater Glasgow and Clyde, 56 NHS Lothian, 57 NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, 58 Norfolk and Norwich University Hospitals NHS Foundation Trust, 59 Norfolk County Council, 60 North Cumbria Integrated Care NHS Foundation Trust, 61 North Middlesex University Hospital NHS Trust, 62 North Tees and Hartlepool NHS Foundation Trust, 63 North West London Pathology, 64 Northumbria Healthcare NHS Foundation Trust, 65 Northumbria University, 66 NU-OMICS, Northumbria University, 67 Path Links, Northern Lincolnshire and Goole NHS Foundation Trust, 68 Portsmouth Hospitals University NHS Trust, 69 Public Health Agency, Northern Ireland, 70 Public Health England, 71 Public Health England, Cambridge, 72 Public Health England,

Colindale, 73 Public Health Scotland, 74 Public Health Wales, 75 Quadram Institute Bioscience, 76 Queen Elizabeth Hospital, Birmingham, 77 Queen's University Belfast, 78 Royal Brompton and Harefield Hospitals, 79 Royal Devon and Exeter NHS Foundation Trust, 80 Royal Free London NHS Foundation Trust, 81 School of Biological Sciences, University of Portsmouth, 82 School of Health Sciences, University of Southampton, 83 School of Medicine, University of Southampton, 84 School of Pharmacy & Biomedical Sciences, University of Portsmouth, 85 Sheffield Teaching Hospitals NHS Foundation Trust, 86 South Tees Hospitals NHS Foundation Trust, 87 Southwest Pathology Services, 88 Swansea University, 89 The Newcastle upon Tyne Hospitals NHS Foundation Trust, 90 The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, 91 The Royal Marsden NHS Foundation Trust, 92 The Royal Wolverhampton NHS Trust, 93 Turnkey Laboratory, University of Birmingham, 94 University College London Division of Infection and Immunity, 95 University College London Hospital Advanced Pathogen Diagnostics Unit, 96 University College London Hospitals NHS Foundation Trust, 97 University Hospital Southampton NHS Foundation Trust, 98 University Hospitals Dorset NHS Foundation Trust, 99 University Hospitals Sussex NHS Foundation Trust, 100 University of Birmingham, 101 University of Brighton, 102 University of Cambridge, 103 University of East Anglia, 104 University of Edinburgh, 105 University of Exeter, 106 University of Kent, 107 University of Liverpool, 108 University of Oxford, 109 University of Sheffield, 110 University of Southampton, 111 University of St Andrews, 112 Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, 113 Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, 114 Watford General Hospital, 115 Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, 116 Wellcome Sanger Institute, 117 West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, 118 Whittington **Health NHS Trust** 

# Acknowledgements

COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC\_PC\_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute.

# **Declaration of Interest**

None.

# **Data Availability Statement**

The data that support the findings of this study are available at Wellcome Sanger Institute COVID–19 Genomic Surveillance (<a href="https://covid19.sanger.ac.uk/lineages/raw">https://covid19.sanger.ac.uk/lineages/raw</a>).

**Table 1**. Estimated rate of spatial growth ( $\bar{t}_{LE}$ ) of sample SARS-CoV-2 lineages in England, September 2020–December 2021.


Variant / lineage	LTLAs (n)	Number of detections <sup>1</sup>	Earliest detection <sup>2</sup> $(t=1)$	$\bar{t}_{LE}$ (95% CI) (weeks)
Alpha (B.1.1.7 and Q)	307	153,405	39/2020 (26 Sept.)	9.90 (9.56, 10.23)
Delta (B.1.617.2 and AY)	307	722,133	12/2021 (27 March)	7.40 (7.12, 7.68)
B.1.617.2	307	17,504	13/2021 (3 April)	9.11 (8.48, 9.74)
AY.3	168	620	27/2021 (10 July)	14.12 (13.26, 14.98)
AY.4	307	547,403	12/2021 (27 March)	9.45 (9.24, 9.66)
AY.4.1	133	416	25/2021 (26 June)	9.50 (8.61, 10.40)
AY.4.2	307	77,391	25/2021 (26 June)	6.21 (5.86, 6.57)
AY.4.2.1	307	11,541	29/2021 (24 July)	9.43 (8.91, 9.94)
AY.4.3	188	781	19/2021 (15 May)	19.93 (18.92, 20.93)
AY.4.5	158	742	24/2021 (19 June)	15.06 (13.76, 16.37)
AY.5	307	26,111	15/2021 (17 April)	9.83 (9.38, 10.28)
AY.6	306	17,405	17/2021 (1 May)	8.88 (8.48, 9.27)
AY.7	276	3,627	18/2021 (8 May)	9.02 (8.39, 9.65)
AY.8	141	1,241	16/2021 (24 April)	8.60 (7.90, 9.29)
AY.9	304	10,136	14/2021 (10 April)	10.88 (10.33, 11.42)
AY.9.2	251	1,990	28/2021 (17 July)	10.44 (9.70, 11.17)
AY.10	118	683	15/2021 (17 April)	8.50 (7.96, 9.04)
AY.25	130	486	31/2021 (7 Aug.)	13.02 (12.26, 13.78)
AY.33	105	319	25/2021 (26 June)	17.84 (16.63, 19.05)
AY.34	268	3,088	30/2021 (31 July)	10.88 (10.19, 11.57)
AY.36	256	1,999	28/2021 (17 July)	12.69 (12.05, 13.32)
AY.42	115	338	27/2021 (10 July)	10.08 (8.81, 11.34)
AY.43	307	23,068	27/2021 (10 July)	5.56 (5.27, 5.86)
AY.46	305	9,461	21/2021 (29 May)	11.23 (10.72, 11.74)
AY.46.5	304	8,649	23/2021 (12 June)	10.13 (9.66, 10.61)
AY.87	172	688	20/2021 (22 May)	10.28 (9.28, 11.29)
AY.89	173	544	21/2021 (29 May)	13.97 (13.17, 14.77)
AY.90	218	1,202	21/2021 (29 May)	13.52 (12.54, 14.50)
AY.98	307	22,465	22/2021 (5 June)	6.34 (5.99, 6.70)
AY.98.1	172	621	25/2021 (26 June)	15.77 (14.80, 16.75)
AY.109	116	441	25/2021 (26 June)	17.59 (16.67, 18.52)
AY.111	296	4,649	21/2021 (29 May)	15.25 (14.46, 16.04)
AY.120	306	18,400	20/2021 (22 May)	6.56 (6.16, 6.97)
AY.122	302	5,018	21/2021 (29 May)	13.80 (13.07, 14.53)
AY.124	119	424	25/2021 (26 June)	12.99 (11.93, 14.05)
AY.125	162	534	26/2021 (3 July)	16.65 (15.79, 17.51)
Omicron (B.1.1.529 and BA)	304	23,137	47/2021 (27 Nov.) <sup>3</sup>	$2.63 (2.56, 2.71)^4$
Average	233	46,450		11.27 (10.03, 12.50)

<sup>&</sup>lt;sup>1</sup> Excludes 1,105 detections for which lineage data is suppressed and 19,550 detections for which lineage data is not available. <sup>2</sup> Epidemiological week/year, with the last day of the week given in parentheses. <sup>3</sup> Excludes a lone detection in week 43 (30 October). <sup>4</sup> Indexed to week 47;  $\bar{t}_{LE}$ = 6.62 (6.53, 6.70) when indexed to week 43.


**Table 2**. Worldwide detection of sample Delta AY lineages with relatively high estimated rates of spatial growth (status: 9 January 2022).

Variant	Countries	Global prevalence (%)	Number of detections	Predominant countries (proportion of global detections)
AY.4.2	52	1	82,038	UK (90%), Denmark (4%), Germany (1%), Poland (1%), France (1%)
AY.43	128	4	267,426	Germany (15%), UK (13%), Denmark (13%), France (12%), Belgium (5%)
AY.98	66	1	41,507	UK (91%), USA (2%), Germany (1%), Denmark (1%), Ireland (1%)
AY.120	74	1	30,320	UK (85%), India (3%), USA (3%), Germany (2%), France (1%)


Sources: data from cov-lineages.org [27] and Latif, et al. [28–31].




**Figure 1.** COVID-19 cases in England, September 2020–December 2021. (A) Positive COVID-19 test specimens as recorded by the UK Government. (B) Number of sample genomes of SARS-CoV-2 in the COG-UK database by variant to 18 December 2021. All data are plotted by week of sample collection. Sources: data from GOV.UK Coronavirus (COVID-19) in the UK [17] and COVID-19 Genomics UK (COG-UK) Consortium [18].




**Figure 2.** Spatial leading edges (*LE*) of the Alpha (B.1.1.7 and Q), Delta (B.1.617.2 and AY) and Omicron (B.1.1529 and BA) variants in England, September 2020–December 2021. The graphs plot, on a weekly basis, the non-cumulative count (upper) and cumulative proportion (lower) of LTLAs in which each of the three variants was first detected. The horizontal (time) axes are indexed to the epidemiological week of first detection (*t* = 1) of the corresponding variant. Average curves, formed across the set of sample lineages in Table 1, are plotted for reference.




**Figure 3.** Spatial leading edges (*LE*) of the Alpha (B.1.1.7 and Q), Delta (B.1.617.2 and AY) and Omicron (B.1.1529 and BA) variants in the LTLAs of England, September 2020–December 2021. Maps are indexed to the epidemiological week of first detection (= week 1) of the corresponding variant and plot the number of weeks to first detection in each LTLA.



**Figure 4.** Spatial leadings edges (*LE*) of the Alpha (B.1.1.7 and Q), Delta (B.1.617.2 and AY) and Omicron (B.1.1529 and BA) variants in the nine standard regions of England, September 2020–December 2021. Maps plot the average time (in weeks) to first detection of a given variant in each regional subset of LTLAs.



**Figure 5.** Estimated rate of spatial growth of sample SARS-CoV-2 lineages in England, September 2020—December 2021. The graph plots values of  $\bar{t}_{LE}$  and associated 95% CI from Table 1. Values are ordered from the lowest (left, high values of  $\bar{t}_{LE}$ ) to the highest (right, low values of  $\bar{t}_{LE}$ ) rates of spatial growth. Values are plotted on an inverted vertical scale to facilitate interpretation. The average value of  $\bar{t}_{LE}$  for the sample is shown for reference.



**Figure 6.** Spatial growth curves for sample Delta sublineages in England, March–December 2021. Curves have been formed in the manner of the lower graphs in Figure 2, with the average curve plotted for reference. Lineages are ordered according to the values of  $\bar{t}_{LE}$  in Table 1 and are defined as having relatively high (i.e. low values of  $\bar{t}_{LE}$ ; upper graphs, A) and relatively low (i.e. high values of  $\bar{t}_{LE}$ ; lower graphs, B) rates of spatial growth.